Innovative Chemistry Platform to Generate Therapeutics for Neurodegenerative Diseases
First-in-class small molecules modulating three complementary upstream mechanisms involved in neurodegeneration
Our Trojan Horse
Ilios is the ancient name of Troy. We are bringing to life a Trojan Horse for the brain to provide an innovative alternative to complex drug discovery.
Modulating three complementary mechanisms: brain inflammation, oxidative stress, and the aggregation of selected misfolded proteins
Novel Chemistry, Validated Agents
Merging privileged bioactive pharmacophores with glutathione and fatty acids to create proprietary New Chemical Entities (NCEs).
Intelligent Drug Discovery
Utilizing a machine learning trained model and a proprietary library to screen through permutations that our platform allows
Facilitating rational design of treatments for several diseases including ALS, Frontotemporal Dementia, Parkinson's, and Alzheimer's
Innovative approach to neurodegeneration
Target multiple complementary mechanisms with a single drug.
First in class NCEs optimized to target multiple pathways upstream neurodegenerative cascade: misfolded protein disaggregation, brain inflammation and oxidative stress.
Synergistic activity in rationally designed NCEs merging validated naturally occurring ligands
Our technology harnesses the potential of Glutathione as a therapeutic linker. Merged with Fatty Acids and other pharmacophores from bioactive polyphenols, our NCEs synergistically modulate multiple mechanisms involved in neurodegeneration
We optimize candidates targeting different pathways: data driven indication strategy
Novel chemical synthesis enables formation of proprietary NCEs from naturally occurring ligands
Abundance of pre-clinical and clinical data demonstrate the biological activity of natural ligands
Benefits of nature-derived bioactive compounds
✓ Superior drug-like properties: stability and oral bioavailability
✓ Increased lipophilicity for enhanced cell penetration
✓ Reduced toxicity and improved safety profile